Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 9Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Ras-mutated Metastatic Colorectal Cancer 1Ovarian Neoplasms 1Lung Neoplasms 1Histiocytosis 1Gastrointestinal Neoplasms 1Gastroesophageal Adenocarcinoma 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Neuroendocrine 1Carcinoma, Basal Cell 1CRC 1Brain Neoplasms 1Advanced Gastric or EGJ Cancer 1

Interventions

Oxaliplatin 16Cetuximab 13Leucovorin 12Fluorouracil 12Bevacizumab 10pembrolizumab 7Specimen Handling 7Nivolumab 7Magnetic Resonance Spectroscopy 6Irinotecan 6Capecitabine 6encorafenib 4Pemetrexed 4Gemcitabine 4Cisplatin 4cemiplimab 3Folfox protocol 3Early Intervention, Educational 3Carboplatin 3Biopsy 3trifluridine tipiracil drug combination 2relatlimab 2pertuzumab 2palbociclib 2fludarabine 2durvalumab 2dehydroftorafur 2aldesleukin 2adagrasib 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × IFL protocol × 90 days × Clear all
NCT03803553 2026-05-01

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Massachusetts General Hospital

Phase 3 Recruiting
400 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡